GAL3 Protein Expression is Related to Clinical Features of Prolactin-Secreting Pituitary Microadenoma and Predicts its Recurrence after Surgical Treatment

Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. Methods: We enrolled 220 patie...

Full description

Saved in:
Bibliographic Details
Published inCellular physiology and biochemistry Vol. 33; no. 4; pp. 1026 - 1035
Main Authors Dai, Dongwei, Li, Ya'nan, Lu, Qiong, Yu, Longyang, Min, Weijie, Wang, Laixing, Cao, Yiqun, Yue, Zhijian
Format Journal Article
LanguageEnglish
Published Basel, Switzerland Cell Physiol Biochem Press GmbH & Co KG 01.01.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. Methods: We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied. Results: We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001). Conclusion: Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients.
AbstractList Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. Methods: We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied. Results: We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001). Conclusion: Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients.
Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. Methods: We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied. Results: We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (Pin vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (PConclusion: Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients.
Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown.BACKGROUNDPrevious in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown.We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied.METHODSWe enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied.We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001).RESULTSWe found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001).Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients.CONCLUSIONGal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients.
Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression with the clinical feature and prognosis of pituitary tumor in a clinical setting remains unknown. We enrolled 220 patients with prolactin-secreting pituitary adenomas (PA) who previously had transsphenoidal pituitary surgery. The Gal-3 expression was detected in the patients' PA samples using immunohistochemistry and those patients were followed up. A prolactin-secreting PA cell line, the MMQ cell line, was used to study the in vitro effect of Gal-3 on proliferation, migration and invasion of PA cells using small interfering RNA (siRNA) transfecton technique. The in vivo tumorgenesis in nude mice was also studied. We found that Gal-3 expression was not related to age and sex, but positively associated with tumor invasion (P<0.001), tumor sizes (P<0.001) and pre-operative prolactin levels (P<0.001). The multivariate Cox analysis showed that the Gal-3 expression was closely associated with the recurrence of PA after the surgical treatment (HR =3.15, P=0.002). The in vitro studies showed that Gal-3 knock-down by the siRNA technique significantly inhibited the proliferation, migration and invasion ability of the MMQ cells, whereas Gal-3 siRNA transfection induced apoptosis of the MMQ cells. The in vivo tumorgenesis assay showed that Gal-3 siRNA transfection significantly inhibited the tumor volume in vivo compared to transfection of the control siRNA (P<0.001). Gal-3 regulates proliferation, apoptosis, migration and invasion of the MMQ cells. Gal-3 may be used as a tissue marker to evaluate the clinical feature and prognosis of PA patients.
Author Min, Weijie
Yu, Longyang
Yue, Zhijian
Dai, Dongwei
Wang, Laixing
Cao, Yiqun
Lu, Qiong
Li, Ya'nan
Author_xml – sequence: 1
  givenname: Dongwei
  surname: Dai
  fullname: Dai, Dongwei
– sequence: 2
  givenname: Ya'nan
  surname: Li
  fullname: Li, Ya'nan
  email: *Zhijian Yue, Department of Neurosurgery, Changhai Hospital,, Second Military Medical University, Shanghai 200433 (China), Tel. +86-021-31161791, Fax +86-021-31161792, E- Mail zhijianyue@sina.cn
– sequence: 3
  givenname: Qiong
  surname: Lu
  fullname: Lu, Qiong
– sequence: 4
  givenname: Longyang
  surname: Yu
  fullname: Yu, Longyang
  email: *Zhijian Yue, Department of Neurosurgery, Changhai Hospital,, Second Military Medical University, Shanghai 200433 (China), Tel. +86-021-31161791, Fax +86-021-31161792, E- Mail zhijianyue@sina.cn
– sequence: 5
  givenname: Weijie
  surname: Min
  fullname: Min, Weijie
– sequence: 6
  givenname: Laixing
  surname: Wang
  fullname: Wang, Laixing
– sequence: 7
  givenname: Yiqun
  surname: Cao
  fullname: Cao, Yiqun
– sequence: 8
  givenname: Zhijian
  surname: Yue
  fullname: Yue, Zhijian
  email: *Zhijian Yue, Department of Neurosurgery, Changhai Hospital,, Second Military Medical University, Shanghai 200433 (China), Tel. +86-021-31161791, Fax +86-021-31161792, E- Mail zhijianyue@sina.cn
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24732466$$D View this record in MEDLINE/PubMed
BookMark eNptkU1vEzEQhleoiH7AgTtClrjAYam9X_YeS9SWSkFEtJytWXscuWzsYHsl-lf6a3G6IQfUk8fWM89Y854WR847LIq3jH5mrO3PKaV1KzpevyhOWFOxsudcHOWasrYUveDHxWmM9zRfeV-9Ko6rhtdV03UnxeP1xbImq-ATWkcu_2wDxmi9IzaSHzhCQk2SJ4vROqtgJFcIacoM8WbXNYJK1pW3qALmYk1WNk02QXgg36wKHjQ6vwECTmcctVUpEpt2bjWFgE4hAZMwkNsprJ8m3IU8YoMuvS5eGhgjvtmfZ8XPq8u7xddy-f36ZnGxLFVTt6k0nWqZ7hQdNArNQKvdLoxQjPNG0b5hVFe6rxrWtXyojBhMS2FATZGbFnh9VtzMXu3hXm6D3eTvSw9WPj34sJYQklUjSoBm6GuAfuhU9nHBuOhzBGpgBgbRZdfH2bUN_veEMcmNjQrHERz6KUrWVqKuBRMso-_36DRsUB8G_8smA59mIO8xxoDmgDAqd7nLQ-6ZPf-PVTmFlINMAez4bMeHueMXhDWGg3ux-jITcqtNpt49S-0lfwGUL8Uf
CitedBy_id crossref_primary_10_3390_genes11030306
crossref_primary_10_1007_s10143_023_02199_7
crossref_primary_10_3389_fphar_2024_1505022
crossref_primary_10_4103_drj_drj_706_23
crossref_primary_10_1111_jne_12352
crossref_primary_10_1007_s11102_015_0674_1
crossref_primary_10_3390_ijms242115719
ContentType Journal Article
Copyright 2014 S. Karger AG, Basel
2014 S. Karger AG, Basel.
Copyright_xml – notice: 2014 S. Karger AG, Basel
– notice: 2014 S. Karger AG, Basel.
DBID M--
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.1159/000358673
DatabaseName Karger Open Access Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: M--
  name: Karger Open Access Journals
  url: https://www.karger.com/OpenAccess
  sourceTypes:
    Enrichment Source
    Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Biology
EISSN 1421-9778
EndPage 1035
ExternalDocumentID oai_doaj_org_article_aa4b93aa9b6c416781789115cb1fab86
24732466
10_1159_000358673
358673
Genre Journal Article
GroupedDBID ---
0R~
0~B
29B
30W
326
36B
3O.
4.4
53G
5GY
5VS
6J9
8UI
AAFWJ
AAYIC
ACGFO
ACGFS
ADBBV
AENEX
AEYAO
AFPKN
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BCNDV
CS3
CYUIP
DIK
DU5
E0A
E3Z
EBS
EJD
EMB
EMOBN
F5P
FB.
GROUPED_DOAJ
HZ~
IPNFZ
KQ8
KUZGX
M--
ML-
N9A
O1H
O9-
OK1
P2P
RIG
RKO
RNS
SV3
UJ6
7X7
88E
8FI
8FJ
AAYXX
ABBTS
ABUWG
ABWCG
ACQXL
ADAGL
AFKRA
AFSIO
AHFRZ
AIOBO
BENPR
BPHCQ
BVXVI
CAG
CCPQU
CITATION
COF
FYUFA
HMCUK
IAO
IHR
ITC
M1P
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
RXVBD
UKHRP
3V.
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c435t-f6c51d6c0bde8d1adc3586f8c1774c09410d2d9241657b2f8bf50abed0e7f5a73
IEDL.DBID M--
ISSN 1015-8987
1421-9778
IngestDate Wed Aug 27 01:31:15 EDT 2025
Fri Jul 11 02:03:11 EDT 2025
Wed Feb 19 02:35:04 EST 2025
Thu Apr 24 23:07:08 EDT 2025
Tue Jul 01 05:10:44 EDT 2025
Thu Aug 29 12:04:36 EDT 2024
Thu Sep 05 20:30:47 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Pituitary adenomas
Prognosis
Galectin-3
Language English
License Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC)
applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
2014 S. Karger AG, Basel.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c435t-f6c51d6c0bde8d1adc3586f8c1774c09410d2d9241657b2f8bf50abed0e7f5a73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://karger.com/doi/10.1159/000358673
PMID 24732466
PQID 1528338181
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_1528338181
doaj_primary_oai_doaj_org_article_aa4b93aa9b6c416781789115cb1fab86
crossref_primary_10_1159_000358673
crossref_citationtrail_10_1159_000358673
pubmed_primary_24732466
karger_primary_358673
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-01-01
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – month: 01
  year: 2014
  text: 2014-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
– name: Germany
PublicationTitle Cellular physiology and biochemistry
PublicationTitleAlternate Cell Physiol Biochem
PublicationYear 2014
Publisher Cell Physiol Biochem Press GmbH & Co KG
Publisher_xml – name: Cell Physiol Biochem Press GmbH & Co KG
References Kim YS, Jung JA, Kim HJ, Ahn YH, Yoo JS, Oh S, Cho C, Yoo HS, Ko JH: Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5. Biochem Biophys Res Commun 2011;404:96-102.2109413210.1016/j.bbrc.2010.11.071
Asa SL, Ezzat S: The Cytogenesis and Pathogenesis of Pituitary Adenomas. Endocrine Rev 1998;19:798-827.986154610.1210/edrv.19.6.0350
Abucham J, Vieira TC: [Glycoprotein-secreting pituitary adenomas: pathogenesis, diagnosis and treatment]. Arq Bras Endocrinol Metabol 2005;49:657-673.1644434910.1590/S0004-27302005000500007
Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A: Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010;127:2530-2541.2016256610.1002/ijc.25254
Zhang S, Hou X, Zi S, Wang Y, Chen L, Kong B: Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients. Cell Physiol Biochem 2013;31:525-531.2357122210.1159/000350073
Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF, Jr., Vidal S, Kovacs K, Raz A, Lloyd RV: Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003;63:2251-2255.12727847
Gavrilov K, Saltzman WM: Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012;85:187-200.22737048
Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordon-Cardo C, Sanchez-Carbayo M: Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010;31:277-285.2040155810.1007/s13277-010-0033-9
Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M: Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005;36:908-914.1611200810.1016/j.humpath.2005.06.020
Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K et al: Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994;76:597-598.812470410.1016/0092-8674(94)90498-7
Raiti S: Pituitary adenomas and other tumors: review in perspective of diagnosis and treatment. Childs Brain 1982;9:147-155.704959810.1159/000120050
Hou X, Hu Z, Huang X, Chen Y, He X, Xu H, Wang N: Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. J Mol Med (Berl) 2013 [Epub ahead of print].2437094010.1007/s00109-013-1099-9
Honjo Y, Nangia-Makker P, Inohara H, Raz A: Down-Regulation of Galectin-3 Suppresses Tumorigenicity of Human Breast Carcinoma Cells. Clinical Cancer Research 2001;7:661-668.11297262
Huang ZL, Liu HY: [Expression of galectin-3 in liver metastasis of colon cancer and the inhibitory effect of modified citrus pectin]. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1358-1361.18753060
Huang C, Li M, Chen C, Yao Q: Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008;12:637-645.1841024510.1517/14728222.12.5.637
Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV: Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas. Endocr Pathol 2005;16:107-114.1619989510.1385/EP:16:2:107
Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H: Reduced Galectin-3 Expression is an Indicator of Unfavorable Prognosis in Gastric Cancer. Anticancer Res 2006;26:1369-1376.16619546
Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R: Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 2013;154:1247-1259.2338483610.1210/en.2012-1908
Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A, Kubo T: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000;6:4635-4640.11156213
van den Brule FA, Waltregny D, Liu FT, Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89:361-367.1095641110.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.0.CO;2-U
Buatti JM, Marcus RB Jr: Pituitary adenomas: current methods of diagnosis and treatment. Oncology 1997;11:791-796.9189937
Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010;176:2067-2081.2036392110.2353/ajpath.2010.090353
Ciric I, Rosenblatt S, Kerr W Jr, Lamarca F, Pierce D, Baumgartner C: Perspective in pituitary adenomas: an end of the century review of tumorigenesis, diagnosis, and treatment. Clin Neurosurg 2000;47:99-111.11197730
Wang SL, Yao HH, Qin ZH: Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther 2009;9:1357-1368.1976141710.1517/14712590903236843
Xu XC, el-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815-822.7677193
Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994;33:14109-14114.794782110.1021/bi00251a020
Asha Das E, Wan-Loo Tan E, Smith DR: Expression of extracellular matrix markers in benign meningiomas. Neuropathology 2003;23:275-281.1471954210.1046/j.1440-1789.2003.00512.x
Barondes SH, Cooper DN, Gitt MA, Leffler H: Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-20810.8063692
Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.1676118910.1007/s10557-006-7652-9
Chanson P, Salenave S: Diagnosis and treatment of pituitary adenomas. Minerva Endocrinol 2004;29:241-275.15765032
Califice S, Castronovo V, Van Den Brule F: Galectin-3 and cancer. Int J Oncol 2004;25:983-992.15375548
Cay T: Immunhistochemical expression of galectin-3 in cancer: a review of the literature. Turk Patoloji Derg 2012;28:1-10.2220742510.5146/tjpath.2012.01090
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-720.864677910.1016/S0092-8674(00)81237-4
Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, Salmon I: Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest 2008;88:896-906.1854204810.1038/labinvest.2008.54
Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF, Vidal S, Kovacs K, Raz A, Lloyd RV: Differential Expression of Galectin-3 in Pituitary Tumors. Cancer Research 2003;63:2251-2255.12727847
Moutsatsos IK, Davis JM, Wang JL: Endogenous lectins from cultured cells: subcellular localization of carbohydrate-binding protein 35 in 3T3 fibroblasts. J Cell Biol 1986;102:477-483.351107110.1083/jcb.102.2.477
Hou X, Appleby N, Fuentes T, Longo LD, Bailey LL, Hasaniya N, Kearns-Jonker M: Isolation, Characterization, and Spatial Distribution of Cardiac Progenitor Cells in the Sheep Heart. J Clin Exp Cardiolog 2012;S6:pii:004.2353967510.4172/2155-9880.S6-004
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-744.864678110.1016/S0092-8674(00)81239-8
Righi A, Jin L, Zhang S, Stilling G, Scheithauer BW, Kovacs K, Lloyd RV: Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol 2010;326:8-14.2045157710.1016/j.mce.2010.04.026
Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H-RC, Raz A: Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest. J Biol Chem 2002;277:6852-6857.1172477710.1074/jbc.M107668200
Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS: Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep 2008;20:1403-1408.1902072110.3892/or_00000159
Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner J: Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol 2006;132:51-56.1618437910.1007/s00432-005-0040-1
Jing M, Li B, Hou X, Shoba J, Li C, Liang H, Zhang X, Liu E, Yang B, Meng X: OPN Gene Polymorphism and the Serum OPN Levels Confer the Susceptibility and Prognosis of Ischemic Stroke in Chinese Patients. Cell Physiol Biochem 2013;32:1798-1807.2435593210.1159/000356613
References_xml – reference: Righi A, Jin L, Zhang S, Stilling G, Scheithauer BW, Kovacs K, Lloyd RV: Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol 2010;326:8-14.2045157710.1016/j.mce.2010.04.026
– reference: Moutsatsos IK, Davis JM, Wang JL: Endogenous lectins from cultured cells: subcellular localization of carbohydrate-binding protein 35 in 3T3 fibroblasts. J Cell Biol 1986;102:477-483.351107110.1083/jcb.102.2.477
– reference: Zhang S, Hou X, Zi S, Wang Y, Chen L, Kong B: Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients. Cell Physiol Biochem 2013;31:525-531.2357122210.1159/000350073
– reference: Asa SL, Ezzat S: The Cytogenesis and Pathogenesis of Pituitary Adenomas. Endocrine Rev 1998;19:798-827.986154610.1210/edrv.19.6.0350
– reference: Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-744.864678110.1016/S0092-8674(00)81239-8
– reference: Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A: Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010;127:2530-2541.2016256610.1002/ijc.25254
– reference: Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994;33:14109-14114.794782110.1021/bi00251a020
– reference: Kim YS, Jung JA, Kim HJ, Ahn YH, Yoo JS, Oh S, Cho C, Yoo HS, Ko JH: Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5. Biochem Biophys Res Commun 2011;404:96-102.2109413210.1016/j.bbrc.2010.11.071
– reference: Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS: Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep 2008;20:1403-1408.1902072110.3892/or_00000159
– reference: Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010;176:2067-2081.2036392110.2353/ajpath.2010.090353
– reference: Ciric I, Rosenblatt S, Kerr W Jr, Lamarca F, Pierce D, Baumgartner C: Perspective in pituitary adenomas: an end of the century review of tumorigenesis, diagnosis, and treatment. Clin Neurosurg 2000;47:99-111.11197730
– reference: Jing M, Li B, Hou X, Shoba J, Li C, Liang H, Zhang X, Liu E, Yang B, Meng X: OPN Gene Polymorphism and the Serum OPN Levels Confer the Susceptibility and Prognosis of Ischemic Stroke in Chinese Patients. Cell Physiol Biochem 2013;32:1798-1807.2435593210.1159/000356613
– reference: Xu XC, el-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815-822.7677193
– reference: Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV: Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas. Endocr Pathol 2005;16:107-114.1619989510.1385/EP:16:2:107
– reference: Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M: Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005;36:908-914.1611200810.1016/j.humpath.2005.06.020
– reference: Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordon-Cardo C, Sanchez-Carbayo M: Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010;31:277-285.2040155810.1007/s13277-010-0033-9
– reference: Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K et al: Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994;76:597-598.812470410.1016/0092-8674(94)90498-7
– reference: Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A, Kubo T: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000;6:4635-4640.11156213
– reference: Huang C, Li M, Chen C, Yao Q: Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008;12:637-645.1841024510.1517/14728222.12.5.637
– reference: Asha Das E, Wan-Loo Tan E, Smith DR: Expression of extracellular matrix markers in benign meningiomas. Neuropathology 2003;23:275-281.1471954210.1046/j.1440-1789.2003.00512.x
– reference: Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R: Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 2013;154:1247-1259.2338483610.1210/en.2012-1908
– reference: Barondes SH, Cooper DN, Gitt MA, Leffler H: Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-20810.8063692
– reference: Buatti JM, Marcus RB Jr: Pituitary adenomas: current methods of diagnosis and treatment. Oncology 1997;11:791-796.9189937
– reference: Huang ZL, Liu HY: [Expression of galectin-3 in liver metastasis of colon cancer and the inhibitory effect of modified citrus pectin]. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1358-1361.18753060
– reference: Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner J: Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol 2006;132:51-56.1618437910.1007/s00432-005-0040-1
– reference: Hou X, Hu Z, Huang X, Chen Y, He X, Xu H, Wang N: Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. J Mol Med (Berl) 2013 [Epub ahead of print].2437094010.1007/s00109-013-1099-9
– reference: Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H-RC, Raz A: Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest. J Biol Chem 2002;277:6852-6857.1172477710.1074/jbc.M107668200
– reference: Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H: Reduced Galectin-3 Expression is an Indicator of Unfavorable Prognosis in Gastric Cancer. Anticancer Res 2006;26:1369-1376.16619546
– reference: Honjo Y, Nangia-Makker P, Inohara H, Raz A: Down-Regulation of Galectin-3 Suppresses Tumorigenicity of Human Breast Carcinoma Cells. Clinical Cancer Research 2001;7:661-668.11297262
– reference: Gavrilov K, Saltzman WM: Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012;85:187-200.22737048
– reference: Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF, Jr., Vidal S, Kovacs K, Raz A, Lloyd RV: Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003;63:2251-2255.12727847
– reference: Cay T: Immunhistochemical expression of galectin-3 in cancer: a review of the literature. Turk Patoloji Derg 2012;28:1-10.2220742510.5146/tjpath.2012.01090
– reference: Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF, Vidal S, Kovacs K, Raz A, Lloyd RV: Differential Expression of Galectin-3 in Pituitary Tumors. Cancer Research 2003;63:2251-2255.12727847
– reference: Raiti S: Pituitary adenomas and other tumors: review in perspective of diagnosis and treatment. Childs Brain 1982;9:147-155.704959810.1159/000120050
– reference: van den Brule FA, Waltregny D, Liu FT, Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89:361-367.1095641110.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.0.CO;2-U
– reference: Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, Salmon I: Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest 2008;88:896-906.1854204810.1038/labinvest.2008.54
– reference: Abucham J, Vieira TC: [Glycoprotein-secreting pituitary adenomas: pathogenesis, diagnosis and treatment]. Arq Bras Endocrinol Metabol 2005;49:657-673.1644434910.1590/S0004-27302005000500007
– reference: Wang SL, Yao HH, Qin ZH: Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther 2009;9:1357-1368.1976141710.1517/14712590903236843
– reference: Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-720.864677910.1016/S0092-8674(00)81237-4
– reference: Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.1676118910.1007/s10557-006-7652-9
– reference: Califice S, Castronovo V, Van Den Brule F: Galectin-3 and cancer. Int J Oncol 2004;25:983-992.15375548
– reference: Hou X, Appleby N, Fuentes T, Longo LD, Bailey LL, Hasaniya N, Kearns-Jonker M: Isolation, Characterization, and Spatial Distribution of Cardiac Progenitor Cells in the Sheep Heart. J Clin Exp Cardiolog 2012;S6:pii:004.2353967510.4172/2155-9880.S6-004
– reference: Chanson P, Salenave S: Diagnosis and treatment of pituitary adenomas. Minerva Endocrinol 2004;29:241-275.15765032
SSID ssj0015792
Score 2.0574076
Snippet Background: Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of...
Previous in vitro study showed that Galectin-3 (Gal-3) protein plays an important role in pituitary tumorigenesis, however, the association of Gal-3 expression...
SourceID doaj
proquest
pubmed
crossref
karger
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1026
SubjectTerms Adult
Animals
Apoptosis
Carcinogenesis
Cell Line, Tumor
Cell Movement
Cell Proliferation
Female
Galectin 3 - antagonists & inhibitors
Galectin 3 - genetics
Galectin 3 - metabolism
Galectin-3
Humans
Immunohistochemistry
Male
Mice
Mice, Nude
Middle Aged
Original Paper
Pituitary adenomas
Pituitary Neoplasms - metabolism
Pituitary Neoplasms - pathology
Pituitary Neoplasms - surgery
Prognosis
Prolactin - metabolism
Recurrence
RNA, Small Interfering - metabolism
Transplantation, Heterologous
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pa9VAEF6kIHoRrVVjq6ziwUtoNsnu5h3bR2sRKw_aQm9hf0LwNSnvJWD_Ff_azuwmQUXx4jWZLMvO7M43mdlvCPmgS-FtyWyae4lXcoRLNVMszY0ucqsFV-GG3PlXcXZVfr7m1z-1-sKasEgPHBfuUKlSLwqlFloYAA-yYrKCDcqNZl7pKpBtg8-bgqkxf8DlIuY5GU8rCKtHTiHw3YcheVYJWfziiQJhP3ihb1h_vfk73Axu5_QpeTLiRXoU5_mMPHDtLnkYO0je7ZJHy6lh23Py49PRl4KukHihaenJ97HEtaXNloaaN2dp39GRCXRNEf0NIEM7j1-t8YpDm14gjsRaaLpq-qHp1eaOnmPVnoITqrtRVLUWxDG_029p0-PYJpA8GUdDx3F6MWzCeUovpyr2PXJ1enK5PEvH1gupAfzUp14YzqwwmbauskxZg2vmK8MALhoICVlmcwuxGxNc6txX2vNMaWczJz1XsnhBdtquda8IzXwuVQ7IRwtZQviiBSCK0sFh4LVxVZmQj5MaajPykmN7jHUd4hO-qGeNJeT9LHobyTj-JHSMupwFkD87PACrqkerqv9lVQnZi5YwDzMNfvDb8-XqOL6qb61PyLvJbmpQPuZeVOu6YVszJNFBdMQS8jIa1DxEXkqAtUK8_h8z3yePAdOV8S_RAdnpN4N7A7ip12_DFrkHlGUTfw
  priority: 102
  providerName: Directory of Open Access Journals
Title GAL3 Protein Expression is Related to Clinical Features of Prolactin-Secreting Pituitary Microadenoma and Predicts its Recurrence after Surgical Treatment
URI https://karger.com/doi/10.1159/000358673
https://www.ncbi.nlm.nih.gov/pubmed/24732466
https://www.proquest.com/docview/1528338181
https://doaj.org/article/aa4b93aa9b6c416781789115cb1fab86
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELagCNELglIgUCqDOHCxWCexnT22q5YKsWiltlJvkZ9VxJJUu4nU_hV-LTPOA4Ho1RnbisePbzzjbwj5aHIZXM4dS4PCJznSM8M1Z6k1WeqMFDq-kFt-l2eX-dcrcTXcd-BbmB8Y_xypUSduAThwP0ePVyFV9pA8Ajsqw-C9JWOTv0Coee_X5IIVYEYPHEJ_VUXe31wBgIiMiH8OocjVDwdQ3_X9SDOeOKfPyNMBKtKjXrfPyQNf75HHffLIuz3yZDHmantBfn05-pbRFXIuVDU9uR2iW2tabWkMd_OOtg0dSEDXFIFfBzK0CVhrja8banaOEBLDoOmqaruq1Zs7usSAPQ2bU_NTU107EEfXTrulVYtt28jvZD2NycbpebeJWym9GAPY98nl6cnF4owNWReYhXFtWZBWcCftzDhfOK6dxeELheWAFC1Yg3zmUgdmG5dCmTQUJoiZNt7NvApCq-wl2amb2r8mdBZSpVMAPUaqHCwXIwFM5B72gWCsL_KEfBrVUNqBkhwzY6zLaJqIeTkpLyEfJtGbnofjf0LHqMtJAKmzY0GzuS6HlVhqnZt5pvXcSAv_oAquCtjxhTU8aFPIhOz3M2FqZmz84J_yxeq4_1TeuJCQ9-O8KUH56HbRtW-6bcmRPweBEU_Iq35CTU2ME_LNPZ2-JbuA0PL-zueA7LSbzr8DFNSaw3h7cBiXwW8EqgBy
linkProvider Karger AG
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELagCJULglIgUMAgDlws4iS2k2O7allgt1qpW6m3yE8UsSTVbiLRv8KvxeM8EIhek7GtZPz4xjPzDULvVcadyaghiROQksMtUVRSkmiVJkZxJkOG3PKczy-zL1fsarjvgFyY7xD_HKhRJ24Bf-B-DB6vnIv0LronCl4AS_6SkMlfwETR-zUpI7k3owcOob-aAu9vJjyACIyIfw6hwNXvD6B-6NuRZjhxzh6hhwNUxMe9bh-jO7Y-QPf74pE3B2h_NtZqe4J-fTpepHgFnAtVjU9_DtGtNa52OIS7WYPbBg8koBsMwK_zMrhx0GoD2Q01uQAICWHQeFW1XdXK7Q1eQsCe9JtT80NiWRsvDq6ddoerFvrWgd9JWxyKjeOLbhu2UrweA9gP0eXZ6Xo2J0PVBaI9dGqJ45pRw3WsjM0NlUbD73O5ph4pam8N0tgkxpttlDOhEpcrx2KprImtcEyK9Cnaq5vaPkc4domQiQc9iovMWy6KezCRWb8POKVtnkXow6iGUg-U5FAZY1MG04QV5aS8CL2bRK97Ho7_CZ2ALicBoM4OD5rtt3JYiaWUmSpSKQvFtf8GkVOR-x2faUWdVDmP0GE_E6Zuxs6P_nk-W530r8pr4yL0dpw3pVc-uF1kbZtuV1LgzwFgRCP0rJ9QUxfjhHxxy6Bv0P58vVyUi8_nX1-iBx6tZf39zxHaa7edfeURUateh8XwG0z9AnU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GAL3+protein+expression+is+related+to+clinical+features+of+prolactin-secreting+pituitary+microadenoma+and+predicts+its+recurrence+after+surgical+treatment&rft.jtitle=Cellular+physiology+and+biochemistry&rft.au=Dai%2C+Dongwei&rft.au=Li%2C+Ya%27nan&rft.au=Lu%2C+Qiong&rft.au=Yu%2C+Longyang&rft.date=2014-01-01&rft.eissn=1421-9778&rft.volume=33&rft.issue=4&rft.spage=1026&rft_id=info:doi/10.1159%2F000358673&rft_id=info%3Apmid%2F24732466&rft.externalDocID=24732466
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1015-8987&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1015-8987&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1015-8987&client=summon